==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1120 which contains 4 entries.


Entry 1
(1) Primary information
ID1556
ThPP IDTh1120
Therapeutic Peptide/Protein NameTeriparatide
SequenceParathyroid hormone precursor - Homo sapiens (1-34 view full sequnce in fasta
Functional ClassificationIb
Molecular Weight4117.715
Chemical FormulaC181H291N55O51S2
Isoelectric PointN.A.
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionRecombinant, human parathyroid hormone (PTH). It is a potent anabolic agent used to treat osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Indication/DiseaseFor the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
PharmacodynamicsClinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.
Mechanism of ActionTeriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.
ToxicityEffects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.
MetabolismHepatic
AbsorptionBioavailability is 95% following subcutaneous injection.
Volume of Distribution0.12 L/kg
Clearance62 L/hr [Women] 94 L/hr [Men]
CategoriesBone Density Conservation Agents
Patents NumberUS6977077
Date of Issue20/08/03
Date of Expiry20/08/23
Drug InteractionN.A.
TargetParathyroid hormone/parathyroid hormone-related peptide receptor
Information of corresponding available drug in the market
Brand NameForteo
CompanyEli Lilly and Company
Brand DiscriptionFORTEO (teriparatide [rDNA origin] injection) contains recombinant human parathyroid hormone (1-34), and is also called rhPTH (1-34). It has an identical sequence to the 34 N-terminal amino acids (the biologically active region) of the 84-amino acid human parathyroid hormone. Teriparatide has a molecular weight of 4117.8 daltons. Teriparatide (rDNA origin) is manufactured using a strain of Escherichia coli modified by recombinant DNA technology
Prescribed forTreatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture, Increase of Bone Mass in Men with Primary or Hypogonadal Osteoporosis at High Risk for Fracture, Treatment of Men and Women with Glucocorticoid-Induced Osteoporosis at High Risk for Fracture.
Chemical NameN.A.
FormulationEach prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 250 mcg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge, pre-assembled into a delivery device, delivers 20 mcg of teriparatide per dose each day for up to 28 days.
Physcial AppearanceSterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection
Route of AdministrationSubcutaneous
Recommended DosageTreatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture. The recommended dose is 20 mcg subcutaneously once a day. Increase of Bone Mass in Men with Primary or Hypogonadal Osteoporosis at High Risk for Fracture. he recommended dose is 20 mcg subcutaneously once a day.
ContraindicationHypersensitivity to teriparatide or to any of its excipients. Reactions have included angioedema and anaphylaxis
Side EffectsN.A.
Useful Linkhttp://en.wikipedia.org/wiki/Teriparatide, http://www.forteo.com/, http://www.rxlist.com/forteo-drug.htm,
PubMed ID25649182, 25639838, 25598280, 25567777, 25567774, 16872263
3-D StructureTh1120 (View) or (Download)


Entry 2
(2) Primary information
ID1557
ThPP IDTh1120
Therapeutic Peptide/Protein NameTeriparatide
SequenceParathyroid hormone precursor - Homo sapiens (1-34 view full sequnce in fasta
Functional ClassificationIb
Molecular Weight4117.715
Chemical FormulaC181H291N55O51S2
Isoelectric PointN.A.
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionRecombinant, human parathyroid hormone (PTH). It is a potent anabolic agent used to treat osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Indication/DiseaseFor the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
PharmacodynamicsClinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.
Mechanism of ActionTeriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.
ToxicityEffects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.
MetabolismHepatic
AbsorptionBioavailability is 95% following subcutaneous injection.
Volume of Distribution0.12 L/kg
Clearance62 L/hr [Women] 94 L/hr [Men]
CategoriesBone Density Conservation Agents
Patents NumberUS6770623
Date of Issue09/12/02
Date of Expiry09/12/22
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID25649182, 25639838, 25598280, 25567777, 25567774, 16872263
3-D StructureTh1120 (View) or (Download)


Entry 3
(3) Primary information
ID1558
ThPP IDTh1120
Therapeutic Peptide/Protein NameTeriparatide
SequenceParathyroid hormone precursor - Homo sapiens (1-34 view full sequnce in fasta
Functional ClassificationIb
Molecular Weight4117.715
Chemical FormulaC181H291N55O51S2
Isoelectric PointN.A.
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionRecombinant, human parathyroid hormone (PTH). It is a potent anabolic agent used to treat osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Indication/DiseaseFor the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
PharmacodynamicsClinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.
Mechanism of ActionTeriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.
ToxicityEffects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.
MetabolismHepatic
AbsorptionBioavailability is 95% following subcutaneous injection.
Volume of Distribution0.12 L/kg
Clearance62 L/hr [Women] 94 L/hr [Men]
CategoriesBone Density Conservation Agents
Patents NumberCA2314313
Date of Issue09/02/09
Date of Expiry09/12/22
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID25649182, 25639838, 25598280, 25567777, 25567774, 16872263
3-D StructureTh1120 (View) or (Download)


Entry 4
(4) Primary information
ID1559
ThPP IDTh1120
Therapeutic Peptide/Protein NameTeriparatide
SequenceParathyroid hormone precursor - Homo sapiens (1-34 view full sequnce in fasta
Functional ClassificationIb
Molecular Weight4117.715
Chemical FormulaC181H291N55O51S2
Isoelectric PointN.A.
HydrophobicityN.A.
Melting Point (℃)N.A.
Half LifeN.A.
DescriptionRecombinant, human parathyroid hormone (PTH). It is a potent anabolic agent used to treat osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Indication/DiseaseFor the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
PharmacodynamicsClinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.
Mechanism of ActionTeriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.
ToxicityEffects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.
MetabolismHepatic
AbsorptionBioavailability is 95% following subcutaneous injection.
Volume of Distribution0.12 L/kg
Clearance62 L/hr [Women] 94 L/hr [Men]
CategoriesBone Density Conservation Agents
Patents NumberCA2325371
Date of Issue18/08/08
Date of Expiry20/08/23
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID25649182, 25639838, 25598280, 25567777, 25567774, 16872263
3-D StructureTh1120 (View) or (Download)